Tylenol

Shareholders Approve Kimberly-Clark’s $40B Acquisition of Tylenol Maker Kenvue

by | Jan 29, 2026
Kimberly-Clark Chairman and CEO Mike Hsu said the milestone "advances our efforts to create a preeminent global health and wellness leader that will raise the standard of care for billions of people around the world and generate significant value for shareholders."
MORE
North Texas’ Kimberly-Clark To Acquire Tylenol Maker in $40B Deal
by | Nov 3, 2025
New Jersey-based Kenvue—which spun off from Johnson & Johnson in 2023—is the maker of Tylenol, whose active ingredient, acetaminophen, has been linked to autism by the Trump administration. Kimberly-Clark CEO Mike Hsu says the unique combination of CPG and healthcare brands "will serve billions of consumers across every stage of life."
MORE